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Introduction: The consequence of insufficient suppression of increased activity of platelets 
can be a repeated cardiovascular event. The most important determinants of the difference in the 
effectiveness of clopidogrel use between patients are two variants of the genotype with loss of 
function in the CYP2C19 gene (*2 and *3), which encodes the cytochrome P450 2C19 enzyme. 
Methods: The study included 34 patients with ischemic heart disease, after a recent 
myocardial revascularization with stenting. Pharmacogenetic testing for the determination of allelic 
variants (polymorphisms) of the CYP2C19 gene was carried out by polymerase chain reaction 
(PCR) in RealTime mode using "DNA-EXPRESS-BLOOD" reagents sets "Liteh", Moscow. 
Statistical processing was performed using the SPSS program: descriptive statistics, Student's t-test 
for independent samples, Chi-square, ROC analysis. 
Results: A total of 34 patients were examined, with an average age of 61.7(cf. 11.4) years. 
Male 23(67.6%) at the age of 55.5(compare off 8.9) years, women 11(32.4%) at the age of 
61.2(compare off 6.9) years. Kazakh nationality 23(67.6%), the European race - 11(32.4%). In the 
history: PCI with stenting, reception of DAT (aspirin with clopidogrel). Stents with drug coating 
28(82.4%), without drug coating 6(17.6%). According to the diameter of the stents to 2.75 mm 
14(41.2%), 3 mm and more than 20(58.8%). For recurrent coronary events: there is no event 
18(52.9%), stent thrombosis 6(17.6%), recurrent angina 10(29.4%). A weak positive correlation 
was found between the development of stent thrombosis from genetic manifestations (r=0.35, 
p=0.43). Genetic testing was performed: 1 - wild type 21 homozygote (61.8%), 2 - heterozygous 
11(32.4%), 3 - homozygous mutation 2(5.9%). All patients are divided into groups by nationality 
and genetic changes. The differences found in the groups are not significant (p = 0.140). The 
statistical significance of genetic testing for the prediction of stent thrombosis has been revealed 
(OR 6.708 CI 95% (1.355-33.209), p=0.02). 
Conclusion: Polymorphism CYP2C19*2(G681A) has a prognostic value in the 
development of stent thrombosis in patients after myocardial revascularization against the 
background of DAT ASA and clopidogrel (OR 6.708 CI 95% (1.355-33.209), p=0.02). 
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